GEA
IDXX icon

Glen Eagle Advisors’s Idexx Laboratories IDXX Stock Holding History

Glen Eagle Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$896K Sell
1,702
-354
-17% -$199K 0.11% 127
2026
Q1 		$1.16M Buy
2,056
+2,026
+6,753% +$1.3M 0.16% 102
2025
Q4 		$20.3K Buy
+30
New +$20.4K ﹤0.01% 579
2024
Q4 		– Sell
-11
Closed -$5.56K – 1133
2024
Q3 		$5.56K Hold
11
– – ﹤0.01% 744
2024
Q2 		$5.36K Buy
+11
New +$5.52K ﹤0.01% 754
2019
Q3 		– Sell
-5
Closed -$1.38K – 837
2019
Q2 		$1.38K Sell
5
-1
-17% -$246 ﹤0.01% 719
2019
Q1 		$1.34K Hold
6
– – ﹤0.01% 682
2018
Q4 		$1.12K Hold
6
– – ﹤0.01% 668
2018
Q3 		$1.5K Hold
6
– – ﹤0.01% 648
2018
Q2 		$1.31K Buy
+6
New +$1.24K ﹤0.01% 639

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Glen Eagle Advisors's IDXX Position: Q2 2026 in Review

Glen Eagle Advisors reduced its Idexx Laboratories (IDXX) stake by 17% in Q2 2026, selling an estimated $199K and leaving 1,702 shares worth $896K. The position accounts for 0.11% of the portfolio, ranked #127.

Glen Eagle Advisors first reported a position in IDXX in Q2 2018 and has held it in 10 quarters since. The position peaked at $1.16M in Q1 2026. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Glen Eagle Advisors held 1,702 shares of Idexx Laboratories worth $896K as of Q2 2026.
  • Glen Eagle Advisors sold 354 Idexx Laboratories shares in Q2 2026, an estimated $199K.
  • Idexx Laboratories made up 0.11% of Glen Eagle Advisors's portfolio in Q2 2026, its #127 holding.
  • Glen Eagle Advisors first reported a position in Idexx Laboratories in Q2 2018 and has held it in 10 quarters since.
  • Glen Eagle Advisors's Idexx Laboratories position peaked at $1.16M in Q1 2026.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.